Windows Vista: Can You Skip It?



By Salvatore Salamone

April 23, 2008 | Those who have been putting off the move to Windows Vista are going to have to make a decision about what to do very soon.

After an earlier extension, Microsoft will no longer provide retailers and computer manufacturers with shrink-wrapped or OEM licenses for Windows XP after June 30. This despite the passionate pleas of ardent users who do not want to make the switch. For instance, as of April 16, 153,623 people had signed InfoWorld’s “Save XP” petition.

For many, the delay in migrating to Vista is fueled by concerns about potential problems when making the move. Some applications, particularly legacy and homegrown apps, may have compatibility problems with Vista. Driver support for lab equipment, printers, input devices, and other gadgets, while rapidly improving, still poses some challenges.

And then there is the cost and time required to perform the migration. Many older PCs must be replaced. And the process of inventorying applications, testing their compatibility, and packaging applications for installation on Vista PCs can consume many days, weeks, or months of an IT staff’s time.

For those trying to decide what to do, Bill Gates’ answer to a question during a speech before the Inter-American Development Bank earlier this month probably just complicated matters more. He indicated (or at least seemed to imply) that the next major version of Windows, dubbed Windows 7, would be available as soon as next year…much sooner than had been anticipated.

So do you migrate to Vista now or wait for Windows 7 and avoid Vista altogether?

A Forrester Research report, “Building the Business Case for Windows Vista,” published this month makes the case that companies should not skip Vista and that they should get migrating as soon as possible. 

Among the reasons Forrester and others give to make the move to Vista rather than wait for Windows 7 include the end of extended support and security patches for Windows XP, the lack of XP availability after June 30, and improved security and user enhancements in Vista.

Some believe the issues surrounding Vista open the door to move to Apple’s Mac OS X or Linux desktop systems.

What do you think? Have you migrated to Vista? Are you planning a migration? Will you wait for Windows 7? Will you switch to another client operating system? Drop me a note at s.salamone@att.net and share your thoughts on the subject.

 


 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .